[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:dnajb1-prkaca":3},{"name":4,"total":5,"recruiting":6,"trials":7},"DNAJB1-PRKACA",3,2,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04248569","DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma",[12],"Phase 1","RECRUITING","2026-08-26T02:19:24.527214Z","2026-05-05T02:43:29.359438Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06027086","DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)",[20],"Phase 1\u002FPhase 2","2026-08-26T02:16:01.079019Z","2026-05-05T02:43:29.321754Z",{"nct_id":24,"title":25,"phases":26,"status":27,"updated_at":28,"content_modified":29},"NCT07430202","A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)",[12],"NOT_YET_RECRUITING","2026-08-26T02:16:27.227548Z","2026-05-05T02:43:26.693770Z"]